• 方向一 糖脂代谢紊乱与代谢性疾病分子机制研究及药物干预

• China Obesity Congress 👩🏻，“The Dual Role of HNF4a in NAFLD and Obesity” ，特邀报告 July 30-31, 2021

• 杏鑫娱乐代谢沙龙华山内分泌会议🕵🏽‍♀️，“Transcriptional regulation of hepatic lipid metabolism and metabolic disorders”🤨，特邀报告July  3,2021

• The 3rd CALS Annual Symposium🙂‍↔️，“Hepatocyte ATF3 protects against diet-induced nonalcoholic fatty liver disease by regulating the HNF4α and bile acid signaling ”👩‍🎤，主题报告October 30-31, 2020

• ATVB 学术会议“Mir34a is a Key Regulator Linking Liver and Macrophages to Atherosclerosis”，主题报告May 5-7, 2020

       本人主要从事代谢性疾病（非酒精性脂肪肝病-NAFLD🪈、动脉粥样硬化-Atheroscerosis/As）糖脂代谢紊乱分子机制研究，力图探寻新的调控糖脂代谢的转录因子👩‍👩‍👦、核受体、非编码小RNA ⚧、信号分子/酶🤳，致力于发现代谢性疾病的致病新通路并转化临床干预疾病的研究。近5年已以第一作者或共同通讯作者发表SCI论文12篇🖐🏿，影响因子累计98.449（第一作者或共同通讯作者论文）。其中1区论文7篇，2区论文1篇。包括代谢领域重要杂志Nature Metabolism, Hepatology, Molecular Therapy, Diabetes, Molecular Metabolism等。研究成果曾获中国脂质与脂蛋白学术会议青年论坛一等奖、湖北省生物化学与分子生物学学术论文二等奖👝、湖北省自然科学优秀学术论文三等奖等奖项👮🏿‍♀️。此外，申请者还担任多个代谢领域知名期刊的审稿人，如J Lipid Res、Front Cell Dev Biol、Atherosclerosis 等杂志。

• 湖北省自然科学优秀学术论文三等奖✈️，湖北省，中国，2016年

• 中国脂质与脂蛋白学术会议第十二届青年论坛一等奖，中国，2015年

• 湖北省生物化学与分子生物学学术论文竞赛二等奖🧑‍✈️，湖北省，中国🦹🏻‍♂️🫶🏼，2014年

发表论文🩵：

       # 第一作者或共同第一作者；*通讯作者

• Yanyong Xu#*, Shuwei Hu#, Kavita Jadhav, Yingdong Zhu, Xiaoli Pan, Liya Yin, Yanqiao Zhang*. Hepatocytic Activating Transcription Factor 3 Protects Against Steatohepatitis Via Hepatocyte Nuclear Factor 4α. Diabetes, 2021. online. (correspondence)

• Yanyong Xu#, Yingdong Zhu#, Shuwei Hu, Xiaoli Pan, Liya Yin, and Yanqiao Zhang*. Hepatocyte miR-34a is a key regulator of the development and progression of non-alcoholic fatty liver disease. Molecular Metabolism, 2021.Apr 28;51:101244. doi: 10.1016/j.molmet.2021.101244. Online ahead of print.

• Yanyong Xu #, Yuanyuan Li #, Kavita Jadhav #,   Xiaoli Pan, Yingdong Zhu, Shuwei Hu, Shaoru Chen, Liuying Chen, Yong Tang, Ling Yang, David Q.-H. Wang, Liya Yin, Yanqiao Zhang*.  Hepatocyte ATF3 protects against atherosclerosis by regulating HDL and bile acid metabolism. Nature Metabolism, 2021; 3:59-74. (Nature 子刊)

• Yanyong Xu #, Yingdong Zhu, Shuwei Hu, Yang Xu, Diane Stroup, Xiaoli Pan, Fathima Cassim Bawa, Shaoru Chen, Raja Gopoju, Liya Yin, and Yanqiao Zhang*. Hepatocyte Nuclear Factor 4α prevents the steatosis-to-NASH progression by regulating the P53 and bile acid signaling. Hepatology. 2020 Oct 23. doi: 10.1002/hep.31604. Online ahead of print.

• Yanyong Xu #, Yang Xu #, Yingdong Zhu#, Huihui Sun, Cody Juguilon, Feng Li, Daping Fan, Liya Yin, and Yanqiao Zhang*. Macrophage MiR-34a Is A Key Regulator of Cholesterol Efflux and Atherosclerosis. Molecular Therapy, 2020 ;28:202-216. (Cell 子刊)

• Yanyong Xu#, Xiaoli Pan#, Shuwei Hu#, Yingdong Zhu, Fathima Cassim Bawa, Yuanyuan Li, Liya Yin, and Yanqiao Zhang*. Hepatocyte-Specific Expression of Human Carboxylesterase 2 Attenuates Non-alcoholic Steatohepatitis in Mice. Am J Physiol Gastrointest Liver Physiol. 2021 ;320(2):G166-G174.

• Yanyong Xu #, Yingdong Zhu, Fathima Cassim Bawa, Shuwei Hu, Xiaoli Pan, Liya Yin, and Yanqiao Zhang*. Hepatocyte-specific Expression of Human Carboxylesterase 1 Attenuates Diet-induced Steatohepatitis and Hyperlipidemia. Hepatology communications, 2020 ;4:527-539.

• Yanyong Xu #, Feifei Li#, Xiaojie Zhao, Chenkun Tan, Binyi Wang, Yiyong Chen, Jia Cao, Dongfang Wu and Hong Yu*. Methionine sulfoxide reductase A attenuates atherosclerosis via repairing dysfunctional HDL in scavenger receptor class B type I deficient mice. The FASEB Journal, 2020 ;34:3805-3819.

• Yanyong Xu #, Yingdong Zhu, Kavita Jadhav, Yuanyuan Li, Huihui Sun, Liya Yin, Takhar Kasumov, Xiaoli Chen, and Yanqiao Zhang*. Lipocalin-2 Protects Against Diet-induced Non-alcoholic Fatty Liver Disease by Targeting Hepatocytes. Hepatology Communications, 2019;3:763-775.

• Yanyong Xu #, Hongmei Liu #, Mengting Liu, Feifei Li, Liangchen Liu, Fen Du, Daping Fan, Hong Yu*. A human apolipoprotein E mimetic peptide reduces atherosclerosis in aged apolipoprotein E null mice. American Journal of Translational Research, 2016; 8:3482-3492.